Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.40 |
| ▸ | NRP1 | O14786 | 7/20 | 0.40 |
| ▸ | LARS1 | Q9P2J5 | 4/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.35 |
| ▸ | NPR1 | P16066 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067570 | 0.87 | NRP1 (0.55) | F2F10PLGPLAUST14 | |
| SCHEMBL13552534 | 0.85 | NRP1 (0.53) | F2NRP1NPR1 | |
| SCHEMBL13552586 | 0.84 | NRP1 (0.43) | NRP1NPR1 | |
| SCHEMBL13552638 | 0.80 | NRP1 (0.44) | F2F10NRP1NPR1 | |
| SCHEMBL13552604 | 0.80 | NRP1 (0.40) | NRP1NPR1 | |
| SCHEMBL13552593 | 0.80 | HDAC3 (0.42) | F2F10NRP1 | |
| SCHEMBL13552573 | 0.79 | NRP1 (0.41) | NRP1PTGES2NPR1 | |
| SCHEMBL13552592 | 0.79 | NRP1 (0.48) | NRP1NPR1 | |
| SCHEMBL13552613 | 0.79 | NRP1 (0.35) | NRP1NPR1 | |
| SCHEMBL10081980 | 0.78 | NRP1 (0.54) | NRP1LARS1NPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | F2 2358/4885F10 3292/4885PLG 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.